Literature DB >> 25356691

Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt.

A Edris1, M O Nour2, O O Zedan2, A E Mansour2, A A Ghandour2, T Omran3.   

Abstract

Hepatitis B and C virus (HBV and HCV) infections remain major public health problems in Egypt and data are needed on risk factors for infection. This study determined the prevalence of anti-HCV and HBV surface antigen seropositivity in Damietta Governorate, Egypt, and evaluated potential risk factors for infection and the impact of HBV vaccination on seroprevalence. A household, cross-sectional study was conducted of 2977 individuals. About 20% were vaccinated against HBV. Only 1.1% were infected with HBV and 9.3% with HCV; both infections coexisted in 12 people (0.4%) (all unvaccinated). The main risk factors for both HCV and HBV were exposure to dental procedures, surgery, stitches, schistosomiasis treatment and contact with infected person. HBV and HCV prevalences in Damietta were lower than the national rate, likely due to the routine compulsory HBV vaccination in those aged < 19 years. There is a need to educate the general population about HBV and HCV transmission routes and avoidance of risky behaviours.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25356691

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  9 in total

1.  Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey.

Authors:  Adebola T Olayinka; Akin Oyemakinde; Muhammad S Balogun; Anthonia Ajudua; Patrick Nguku; Moses Aderinola; Abiodun Egwuenu-Oladejo; Simeon W Ajisegiri; Samuel Sha'aibu; Bolanle O P Musa; Saheed Gidado; Abdulsalami Nasidi
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

Review 2.  Schistosomiasis, hepatitis B and hepatitis C co-infection.

Authors:  Gasim I Gasim; Abdelhaleem Bella; Ishag Adam
Journal:  Virol J       Date:  2015-02-08       Impact factor: 4.099

3.  Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt.

Authors:  Yousry Esam-Eldin Abo-Amer; Sherief Abd-Elsalam; Hazim Eldosoky; Amira K ELShenawy; Shereen Awny; Waleed Elagawy; Mohamed El Abgeegy; Heba Fadl Elsergany; Heba Elashry; Manal Saad Negm
Journal:  Infect Drug Resist       Date:  2018-11-22       Impact factor: 4.003

4.  Prevalence of HCV Infection in Household Contacts of Chronic Liver Diseases Cases in Egypt.

Authors:  Hanaa E Bayomy Helal; Abdelmoniem Yuonis; Rania H M Shaker; Mona Ahmed Elawady
Journal:  J Environ Public Health       Date:  2018-10-24

5.  Hepatitis B and C prevalence among hemodialysis patients in the West Bank hospitals, Palestine.

Authors:  Hamzeh Al Zabadi; Hani Rahal; Rasha Fuqaha
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

Review 6.  Burden of Gastrointestinal and Liver Diseases in Middle East and North Africa: Results of Global Burden of Diseases Study from 1990 to 2010.

Authors:  Sadaf Ghajarieh Sepanlou; Fatemeh Malekzadeh; Farnaz Delavari; Mohsen Naghavi; Mohammad Hossein Forouzanfar; Maziar Moradi-Lakeh; Reza Malekzadeh; Hossein Poustchi; Akram Pourshams
Journal:  Middle East J Dig Dis       Date:  2015-10

Review 7.  Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions.

Authors:  Silva P Kouyoumjian; Hiam Chemaitelly; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

8.  Cross-infection and infection control in dentistry: Knowledge, attitude and practice of patients attended dental clinics in King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Authors:  Nahla K Ibrahim; Hebah A Alwafi; Samaa O Sangoof; Asraa K Turkistani; Bushra M Alattas
Journal:  J Infect Public Health       Date:  2016-07-14       Impact factor: 3.718

9.  Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives.

Authors:  Hanan Hassan Omar
Journal:  Hepat Med       Date:  2019-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.